The new CerroZone indoor air purification system achieved a 99.9684% reduction of live COVID-19 in a single pass in under 30 seconds, according to independent testing at the University of Missouri Laboratory for Infectious Disease Research.
“We are thrilled with the dramatic results confirmed by LIDR and are excited to prepare the product for market launch,” commented Michael Duggan, president of CerroZone LLC. Duggan said CerroZone plans to initially launch two product configurations, a mobile unit and a wall/ceiling mounted unit.
Unlike UV-C based systems, CerroZone will offer the market a compelling value proposition without need of frequent replacement of expensive UV bulbs and accessories.
CerroZone will apply under Section 510(k) of the Food, Drug and Cosmetic Act, which requires device manufacturers to notify the FDA of their intent to market a medical device at least 90 days before launching the product. The patent-pending system was developed in conjunction with Micron Pure, a Hecto Group company.
For more info, visit www.CerroZone.com.